Forum pracy nad projektem wskrzeszenia The Forge

[02fdd68lv]

Potassium-magnesium aspartate in the treatment of congestive heart failure in the sense


: Before and after treatment were observed in patients with clinical symptoms, heart rate, cardiac function,[link widoczny dla zalogowanych], ECG situation. Evaluation standard 1.4: improved heart function above the level I or level I reached was markedly cardiac function, cardiac function was improved as a valid I-level, less than I level or exacerbations is invalid. 1.5 Statistical analysis: The test. 2 Results 2.1 The changes of cardiac function before and after treatment in both groups in Table 1. ,[link widoczny dla zalogowanych], / 48,[link widoczny dla zalogowanych], Table 1,[link widoczny dla zalogowanych], changes in heart function before and after treatment in both groups 2.2 Comparison of two groups: treatment group: 14 cases markedly effective (48.2. Effective,[link widoczny dla zalogowanych], 13 cases (44.82), 2 cases. Control group: 9 cases markedly. Effective in 14 cases. 4 cases. The efficiency of the two groups were compared P <0.05. 2.3 Comparison of the onset time of two groups in Table 2. Table 2 Comparison of two treatment time from rising efficiency improvement of symptoms after treatment time (h) group significantly improved chest tightness, shortness of breath moist rales in the lung disappeared rate and compare the onset time of the two groups P <0.05. 2.4 two arrhythmia after treatment comparison group: 5 cases of ventricular premature treatment group disappeared, ventricular premature disappearance rate of 62.5; 1 case of frequent PVCs, 2 occasional room early. 4 cases of ventricular premature control group disappeared. PVCs disappeared was 44.44, 2 cases are still frequent PVCs. 3 cases of accidental room early. Room rates compared two groups disappeared as early as P <0.05. 2.5 adverse drug events: the treatment group, 2 patients in the intravenous infusion of potassium-magnesium aspartate in dizziness, face flushing, 1 case of vascular pain, the less symptoms disappeared after the slow drip rate. All patients before and after treatment of liver, renal function abnormalities. 3 Discussion 3.1 congestive heart failure (CHF) in patients with varying degrees of hypokalemia hypomagnesemia Ⅲ. CHF time. Renal blood flow decreased. Blood renin _ 4. Guilin Medical Building No. 15 of 1999 I combined dry pipe ... aldosterone system angiotensin (RAAS) is activated. The kidney row K, Mg increased. The low-K for further activation of RAAS, resulting in a vicious circle. Patients with long-term use of row K CttF diuretics. Transport glucose solution, to increase the excretion of potassium and magnesium. These patients led to hypokalemia hypomagnesemia. Magnesium in cardiovascular and cell body in the stable internal environment, several enzymes involved in the activities of the body. Including cellular energy generation and storage, protein synthesis and energy metabolism [2]. Low magnesium on ischemic myocardial energy metabolism. Cause myocardial systolic and diastolic dysfunction. Magnesium supplementation can reverse this mechanism. This treatment of cardiac patients in the conventional diuretic and dilation of blood vessels, based on intravenous infusion of potassium magnesium aspartate. Because of myocardial cells caused by low potassium low magnesium reversal of energy metabolism, improve cardiac function. At the same time passed quickly as magnesium aspartate potassium into cardiac cells, and calcium competition reduces myocardial ischemia]. From the onset time and treatment group were compared with the control group differences in efficiency were significantly (P <O.05), that potassium magnesium aspartate on the treatment of CHF have a certain effect. 3.2 potassium-magnesium aspartate can effectively prevent the occurrence of arrhythmias mouth]. When hypokalemia. Increased cardiac excitability. Abnormal ectopic pacemaker prolonged and increased self-discipline. Prone to arrhythmias. Lack of heart beat can increase excitability. Precipitate tachyarrhythmias. Application of magnesium aspartate potassium chlorate, the rapid increase in myocardial content of magnesium, potassium, both inside and outside. R effective control of arrhythmias. This treatment group rate of loss of ventricular arrhythmia ventricular arrhythmias than the control group was significantly higher disappearance (P <O.05). That when the potassium-magnesium aspartate on the CHF with ventricular arrhythmia prevention and treatment.
More articles related to topics：


[link widoczny dla zalogowanych]

Mulberry handbags Ning suppository too Ⅰ, Ⅱ degr

[link widoczny dla zalogowanych]

[link widoczny dla zalogowanych]

burberry sale Psychiatric nurse in their own quali